申请人:Ugashe Solomon
公开号:US20090118307A1
公开(公告)日:2009-05-07
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
提供了一些化合物,它们作为CCR9受体的有效拮抗剂,并且已经在动物炎症测试中得到了进一步的确认,这是CCR9的标志性疾病状态之一。这些化合物通常是芳基磺酰胺衍生物,可用于制药组合物、CCR9介导疾病的治疗方法,以及用于鉴定CCR9拮抗剂的测定中的对照。